Testosterone Therapy (TRT) Monitoring Schedule

Because a single number can be misleading, and starting lifelong hormone therapy on a bad reading is a real risk. Testosterone naturally swings from day to day and is at its highest in the morning, so the standard from the American Urological Association and the Endocrine Society is two total-testosterone blood tests, both drawn early in the morning, on separate days — and both consistently low — before a diagnosis of testosterone deficiency is made. Just as important, the diagnosis needs symptoms too: consistently low levels without symptoms, or symptoms with normal levels, usually aren't treated as low T. Confirming first protects you from being put on testosterone you don't need.

Because testosterone tells your bone marrow to make more red blood cells, and on therapy that can tip into erythrocytosis — a red-cell count (hematocrit) that climbs too high and thickens the blood. That's why a clinician measures your hematocrit and hemoglobin before you start and then rechecks it, commonly around 3 to 6 months, 12 months, and yearly after that. If it rises too far — a threshold of roughly 54% is widely used — the usual response is to pause therapy, lower the dose, or adjust how it's given, and to look for other contributors like sleep apnea. It's a routine, manageable part of TRT, not a reason to fear it — but it's exactly why the monitoring matters.

Testosterone therapy does not cause prostate cancer, but it can accelerate a cancer that is already present, so clinicians check a PSA blood test and, when appropriate, do a prostate exam before starting and during treatment. The Endocrine Society recommends a baseline PSA in men over 40 to exclude an existing cancer, a recheck within the first 3 to 12 months, and PSA thereafter following normal prostate-cancer screening guidance. A meaningful rise — often described as more than about 1.4 ng/mL above your baseline, or a PSA crossing 4.0 — is a prompt for a urology referral, not an automatic diagnosis. It's surveillance so that anything is caught early, which is the whole point of a monitoring plan.

Yes — and this is the caveat to understand before starting. Taking testosterone from outside suppresses the brain signals (LH and FSH) that tell your testicles to make both testosterone and sperm, so TRT reduces or stops sperm production and can cause infertility. For many men sperm production recovers after stopping, but recovery can take many months and isn't guaranteed. That's why TRT is not recommended for men who are trying to conceive or who may want children in the future. If fertility matters to you, tell your prescriber before you start: there are alternatives that raise testosterone while preserving sperm, and sperm banking is an option. This is a conversation to have first, not a surprise to discover later.

A common cadence is a first review around 3 months after starting, again near 6 months, a fuller check at 12 months, and then roughly yearly once you're stable — but the exact schedule is your prescriber's call and depends on your age, your starting bloodwork, the form of testosterone you use, and how you respond. Early on, visits tend to cluster because that's when the dose is being dialed in and when changes in hematocrit or PSA are most likely to show up. Later, once things are steady, monitoring usually settles into an annual rhythm. The intervals in this planner are the widely-used pattern, offered to help you know what to expect and to ask good questions — not a replacement for the plan your clinician sets with you.

Yes. This planner runs entirely in your browser: the dates and boxes you enter are used on your own device to build your checklist and are never sent to a server, saved, or shared — close the tab and they're gone. There are no accounts and no tracking of your inputs. The output is an educational schedule built from published Endocrine Society and AUA guidance; it isn't medical advice, a diagnosis, or a prescription, and it contains no doses. Your prescriber sets and adjusts the real monitoring plan.